An Unprecedented Collaboration Between Institutions for the Advancement of National Research Interests in Cancer
As the first NCORP Community Site within the state of New Jersey, Atlantic Health Cancer Consortium Community Oncology Research Program (AHCC-CORP) combines the collective strengths of world-class health care systems with community oncology care delivery.
AHCC-CORP covers an area with diverse geography and demographics, representing approximately 70% of New Jersey’s population. The program expands the NCORP network by 6.5 million people; with a higher cancer incidence rate than the US as a whole (477.5 vs 441.2 cases per 100,000). Regions within the AHCC-CORP are even further elevated.
We Aim To:
Enhance community engagement in cancer control and prevention clinical trials and Cancer Care Delivery Research (CCDR) conducted by NCORP in the AHCC-CORP region. CCDR is a science that seeks to improve clinical outcomes and patient well-being by intervening on patient, clinician, and organizational factors that influence care delivery.
Contribute to the development and implementation of clinically significant studies that incorporate the unique research needs of the diverse population within the AHCC-NCORP service area, leveraging the expertise of established oncology specialty physicians and other providers within our affiliate network.
Baseline enrollment data for our first year has demonstrated considerable diversity in NCI trial participants.
- Over 40% of our enrollment has been from pediatric, adolescent and young adult populations.
- Over 30% of our enrollment has been from a non-White population, reflecting the multicultural diversity in the state.
Rosemary Stefiniw, RN
Highlighted Consortium Studies
- Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
- Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (ALCHEMIST)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy